To evaluate the effect of anti-platelet regimens and it’s combination with Shuxinyin (SXY

) on in-stent restenosis after stent implantation. Forty-four patients with successful stent implantation in a coronary artery were randomly assigned to the treated group (n = 20) and the control group (n = 24). The treated group received SXY and anti-platelet therapy. The control group were treated with anti-platelet regimens only. Platelet activation was assessed before and immediately after the stenting by flow cy-tometry

the expression of P-selectin (CD62P) and glycoprotein(GP) П b/Ш a receptor. It was reassessed on the 30th day after stenting. Plasma fibrinogen (Fg) and C-reaction protein (CRP) were measured by biuret and laser scattering turbidimetry respectively at the same time. Observation was made on the scoring of the symptoms of Qi deficiency syndrome

Qi-Yin deficiency syndrome and blood stasis syndrome in the two groups. Differences between groups were compared. Compared with the control group

combination with SXY and anti-platelet therapy was remarkable in reducing plasma CRP (P < 0.05)

and also with the tendency to decrease plasma Fg

GP П b/Шa and CD62P. It could also evidently decrease the scoring of Qi-Yin deficiency syndrome

Qi deficiency syndrome and blood stasis syndrome after stenting (P <0.05

0.01

0.01) respectively. Followup survey found 40 % relapse of angina pectoris with 4 cases of in-stent restenosis proved by angiography in the treated group. But the relapse of angina pectoris in the control group was 67% with 2 cases of mypcardial infarction (MI)

7 cases of in-stent restenosis proved by angiography and one death. Combination with SXY and anti-platelet regimens can prevent stent thrombosis and in-stent restenosis after stent implantation

and it seems superior to anti-platelet therapy only.